| Compound Information | SONAR Target prediction |  | Name: | CYCLOSPORINE |  | Unique Identifier: | SPE01502202  |  | MolClass: |  Checkout models in ver1.5 and ver1.0 |  | Molecular Formula: | C62H111N11O12 |  | Molecular Weight: | 1090.73 g/mol |  | X log p: | 4.12  (online calculus) |  | Lipinksi Failures | 3 |  | TPSA |  |  | Hydrogen Bond Donor Count: | 5 |  | Hydrogen Bond Acceptors Count: | 12 |  | Rotatable Bond Count: | 12 |  | Canonical Smiles: | CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C( =O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C) C)C(=O)N(C)C(C(C)C)C(=O)N1(C) |  | Class: | macrolide |  | Source: | Tolypocladium inflatum |  | Reference: | Helv Chim Acta 60: 1568 (1977) |  | Therapeutics: | immunosuppressant |  | Generic_name: | Cyclosporine |  | Chemical_iupac_name: | Cyclosporine |  | Drug_type: | Approved Drug |  | Pharmgkb_id: | PA449167 |  | Drugbank_id: | BIOD00003 |  | Logp: | 4.293 |  | Cas_registry_number: | 59865-13-3 |  | Drug_category: | Immunmodulatory Agents; Immunosupressants |  | Indication: | For treatment of transplant rejection, rheumatoid arthritis, severe psoriasis |  | Pharmacology: | Used in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2. |  | Mechanism_of_action: | Cyclosporine binds to cyclophillin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and ineterluekin relase. |  | Organisms_affected: | Humans and other mammals |  
 
 
	
		| Species: | 
		4932 | 
	 
	
		| Condition: | 
		pdr_yCG196 | 
	 
	
		| Replicates: | 
		2 | 
	 
	
		| Raw OD Value: r im | 
		0.6345±0.0176777 | 
	 
	
		| Normalized OD Score: sc h | 
		0.8640±0.0221275 | 
	 
	
		| Z-Score: | 
		-4.5453±0.70554 | 
	 
	
		| p-Value: | 
		0.0000262304 | 
	 
	
		| Z-Factor: | 
		0.0882617 | 
	 
	
		| Fitness Defect: | 
		10.5486 | 
	 
	
		| Bioactivity Statement: | 
		Active | 
	 
 
| Experimental Conditions |  |  | Library: | Spectrum_ED |  | Plate Number and Position: | 1|A6 |  | Drug Concentration: | 50.00 nM |  | OD Absorbance: | 595 nm |  | Robot Temperature: | 30.00 Celcius |  | Date: | 2010-08-10 YYYY-MM-DD |  | Plate CH Control (+): | 0.0885±0.00760 |  | Plate DMSO Control (-): | 0.9339999999999999±0.01812 |  | Plate Z-Factor: | 0.9212 |  
  |  png ps pdf |  
 
 
	
		| 6475367 | 
		(3S,6S,9S,12R,15S,18S,21S,24S,30S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12,15, 19,22,25,28-decamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28, 31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone | 
	 
	
		| 6475373 | 
		(3S,6S,9S,12R,15S,18S,21S,24S,27S,30S)-30-ethyl-27-(hydroxymethyl)-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex- 4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,1 0,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone | 
	 
	
		| 6475949 | 
		(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7, 10,12,15,19,28-octamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25, 28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone | 
	 
	
		| 6475950 | 
		(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7, 10,12,15,19,28-octamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tripropan-2-yl-1,4,7,10,13,16,19,22,25,28, 31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone | 
	 
	
		| 6475951 | 
		(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-24-[(2S)-butan-2-yl]-25,30-diethyl-33-[(E,1R,2R)-1-hydroxy-2-meth yl-hex-4-enyl]-1,4,7,10,12,15,19,28-octamethyl-6,9,18-tris(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,1 3,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone | 
	 
	
		| 6476067 | 
		(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,6,7,10, 12,15,19,25,28-decamethyl-9,18,24-tris(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28,31- undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone | 
	 
 
 | internal high similarity DBLink  | Rows returned: 1 |  |   
 |  active | Cluster 1190 | Additional Members: 4 | Rows returned: 0 |  |  
  
 |